Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Sanofi Wins Appeal Against Mylan Over Oncology Drug Patent

Jan. 15, 2021, 3:08 PM

Viatris, formerly Mylan, lost its appeals court bid to invalidate a Sanofi patent on the prostate cancer drug Jevtana.

  • The U.S. Court of Appeals for the Federal Circuit, without issuing a formal opinion, affirmed a Patent Trial and Appeal Board decision that let Sanofi amend the claims of patent 8,927,592 to avoid invalidity arguments raised by Mylan
  • The board had previously invalidated the patent but was ordered by the court in 2019 to consider Sanofi amendments
  • Patent expires in 2031: FDA Orange Book
  • Docket link

To contact the reporter on this story:
Susan Decker in Washington at sdecker1@bloomberg.net

To ...